A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2, RANDOMIZED, DOSE-RANGING, VEHICLE-CONTROLLED AND TRIAMCINOLONE 0.1% CREAM¿CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INCB018424 PHOSPHATE CREAM APPLIED TOPICALLY TO ADULTS WITH ATOPIC DERMATITIS

Intervention/treatment:
RUXOLITINIB (INCB018424)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
INCB 18424-206
Control number:
199502
Status:
Closed
Approved:
November 18, 2016
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03011892
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Incyte Corporation
Phone:
1-855-463-3463
Sponsor
INCYTE CORPORATION

Locations

Alberta

INSTITUTE FOR SKIN ADVANCEMENT, 4935 40th Avenue Nw
Calgary, Alberta, T3A 2N1

British Columbia

DR. CHIH-HO HONG MEDICAL INC., 15300 105 Avenue
Surrey, British Columbia, V3R 6A7

Manitoba

WISEMAN DERMATOLOGY RESEARCH INC, 6 - 1170 Taylor Avenue
Winnipeg, Manitoba, R3M 3Z4

Ontario

CCA MEDICAL RESEARCH, 95 Bayly Street West
Ajax, Ontario, L1S 7K8
DERMEDGE RESEARCH INC., 333 Lakeshore Road West
Mississauga, Ontario, L5H 1G9
K. PAPP CLINICAL RESEARCH, 135 Union Street East
Waterloo, Ontario, N2J 1C4
LYNDERM RESEARCH INC, 25 Main Street Markham North
Markham, Ontario, L3P 1X2
NORTH BAY DERMATOLOGY CENTRE, 500 Cassells Street
North Bay, Ontario, P1B 3Z7
OFFICE OF DR. MICHAEL ROBERN, 1 Centrepointe Drive
Ottawa, Ontario, K2G 6E2
RESEARCH BY ICLS, 1344 Cornwall Road
Oakville, Ontario, L6J 7W5
RESEARCH TORONTO, 208 Bloor Street West
Toronto, Ontario, M5Sz 2B4
SIMCODERM MEDICAL AND SURGICAL DERMATOLOGY CENTER, 5 Quarry Ridge Road
Barrie, Ontario, L4M 7G1
SKIN CENTRE FOR DERMATOLOGY, 775 Monaghan Road
Peterborough, Ontario, K9J 5K2
WINDSOR CLINICAL RESEARCH INC, 2224 Walker Road
Windsor, Ontario, N8W 5L7
XLR8 MEDICAL RESEARCH, 2425 Tecumseh Road East
Windsor, Ontario, N8W 1E6
YORK DERMATOLOGY CENTER, 250 Harding Blvd West
Richmond Hill, Ontario, L4C 9M7

Quebec

CLINIQUE DERMATOLOGIQUE DE SAINT-JEROME, 555 Boul. Saint-antoine
Saint-Jérôme, Quebec, J7Z 3B8

Results

See the results from the trial NCT03011892. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?